Difebarbamate is a barbituric acid derivative. It is a hypnotic drug. Difebarbamate is a component of Tetrabamate complex, which was introduced for clinical use in the treatment of alcoholism and various types of drug dependence. After oral administration of difebarbamate, the compound was completely metabolized and three metabolic pathways were observed: oxidation of Cl of the n-butyl chain which leads to the oxygen dealkylation; hydrolysis of the carbamoyloxy group; oxidation of the benzene ring in position 4. Tetrabamate can induce hepatotoxicity, probably due to an idiosyncratic metabolic mechanism. Despite restrictions on its indications and treatment duration introduced in 1997, cases of severe liver damage have continued to be notified in France.